Evidence map›Paper›PMID 32358729›Full record

ArticleAging clinical and experimental research2021

A National Multicenter Study on overall survival in elderly metastatic castrate-resistant prostate cancer patients treated with Radium-223.

Viviana Frantellizzi, Fabio Monari, Manlio Mascia, Renato Costa, Giuseppe Rubini, Angela Spanu, Alessio Farcomeni, Elisa Lodi Rizzini, Luca Cindolo, Alessandra Murabito and 7 more

Open access · greenAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Aging clinical and experimental research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Radium - from discovery to the present day - narrative review.Clinical and experimental medicine · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 1 country.

Viviana FrantellizziDepartment of Molecular Medicine Sapienza, "Sapienza" University of Rome, Viale Regina Elena 324, 00161, Rome, Italy. viviana.frantellizzi@uniroma1.it.ORCID http://orcid.org/0000-0003-3497-4236
Fabio MonariRadiation Oncology Center, S.Orsola-Malpighi Hospital, Bologna, Italy.
Manlio MasciaUnit of Nuclear Medicine, "Spirito Santo" Hospital, Pescara, Italy.
Renato CostaUnit of Nuclear Medicine, Biomedical Department of Internal and Specialist Medicine, University of Palermo, Palermo, Italy.
Giuseppe RubiniNuclear Medicine Department, University of Bari "Aldo Moro", Bari, Italy.
Angela SpanuUnit of Nuclear Medicine, Department of Medical Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.
Alessio FarcomeniDepartment of Economics & Finance, University of Rome "Tor Vergata", Rome, Italy.
Elisa Lodi RizziniNuclear Medicine Unit, S.Orsola-Malpighi Hospital, Bologna, Italy.
Luca CindoloDepartment of Urology, "Villa Stuart" Private Hospital, Rome, Italy.
Alessandra MurabitoUnit of Nuclear Medicine, Biomedical Department of Internal and Specialist Medicine, University of Palermo, Palermo, Italy.
Valentina LavelliNuclear Medicine Department, University of Bari "Aldo Moro", Bari, Italy.
Susanna NuvoliUnit of Nuclear Medicine, Department of Medical Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.
Laura CosmaDepartment of Radiological Sciences, Oncology and Anatomical Pathology Sapienza, "Sapienza" University of Rome, Rome, Italy.
Valeria DionisiRadiation Oncology Center, S.Orsola-Malpighi Hospital, Bologna, Italy.
Anna Giulia NappiNuclear Medicine Department, University of Bari "Aldo Moro", Bari, Italy.
Marco AndreolaDepartment of Radiological Sciences, Oncology and Anatomical Pathology Sapienza, "Sapienza" University of Rome, Rome, Italy.
Giuseppe De VincentisDepartment of Radiological Sciences, Oncology and Anatomical Pathology Sapienza, "Sapienza" University of Rome, Rome, Italy.
Sapienza University of Rome · ITIRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola · ITUniversity of Bari Aldo Moro · ITUniversity of Palermo · ITUniversity of Sassari · ITOspedale di Santo Spirito · ITUniversity of Rome Tor Vergata · ITVilla Torri Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRadium-223 prolongs overall survival (OS) and delays time to the first symptomatic skeletal events in patients with symptomatic metastatic castration-resistant prostate cancer (mCRPC). There is a lack of evidence on the safety and efficacy of Radium-223 treatment in the very elderly population.

aimsAim of this multicentre study is to analyze mCRPC patients treated with Radium-223 in terms of OS and to assess whether there are differences between young and elderly, as well as to verify efficacy and safety in patients ≥ 75 years of age.

methods430 mCRPC patients of six Italian Centres were analyzed in this multicenter retrospective study. At baseline and after each cycle were collected clinical and diagnostic patients' parameters. The whole cohort was divided into two groups based on the age of the patients (< 75 years old and ≥ 75 years old).

results47% of the patients were < 75 years old and 53% were ≥ 75 years old. The primary outcome, OS, does not show significant differences between the two subgroups if other basal parameters are considered. Considering clinical covariates in univariate models (p < 0.05) several clinical aspects have an impact on OS, except for age (p = 0.072). Age continues to have no significant impact on the OS (p = 0.274) even in multivariate models in the two groups. The toxic effects are similar in the two groups.

conclusionsRadium-223 prolongs survival in both younger and older patients at the same baseline condition and is a good option in the symptomatic mCRPC setting compared to other agents.

Indexed as

Bone NeoplasmsProstatic Neoplasms, Castration-ResistantAgedHumansItalyMaleRadiumRetrospective StudiesRadiumRadium-223ElderlymCRPCOverall survivalProstate cancerRadium-223

Identifiers

PMID32358729
OpenAlexW3022141926

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.